

IN THE CLAIMS:

Kindly cancel claims 7 and 18-20, and rewrite claims 1 and 2 as follows. The status of all of the claims in the application is also set forth below.

1. (Currently Amended) An interface for a transdermal drug administration device having a flat plate formed from polyactic acid comprising a plurality of two-dimensionally arranged conical or pyramidal projections capable of piercing the skin and a plurality of openings spaced from the conical or pyramidal projections and capable of delivering a drug, said openings being ~~which are~~ respectively arranged in correspondence with the projections, wherein ~~the openings are~~ respectively arranged in proximity to their corresponding projections the distance between a particular projection and its corresponding opening is smaller than the distance between the particular projection and an opening that does not correspond thereto.

2. (Currently Amended) The interface for a transdermal drug administration device according to claim 1, wherein channels are provided on the surface of the flat plate between the openings and their corresponding projections for directing a drug from the openings to their corresponding projections ~~are provided between the openings and their corresponding projections on the flat plate.~~

3. (Previously Presented) The interface for a transdermal drug administration device according to claim 1, wherein the projections are 100 to 700 μm in height.

4. (Previously Presented) The interface for a transdermal drug administration device according to claim 1, wherein the lower bases of the projections are 30 to 200 μm in diameter.

5. (Previously Presented) The interface for a transdermal drug administration device according to claim 1, wherein the openings are 50 to 2000 μm in diameter.

6. (Previously Presented) The interface for a transdermal drug administration device according to claim 1, wherein the ratio between the number of the openings and the number of the projections is 1:1 to 1:2.

7. (Cancelled)

8. (Previously Presented) The interface for a transdermal drug administration device according to claim 2, wherein the projections are 100 to 700 μm in height.

9. (Previously Presented) The interface for a transdermal drug administration device according to claim 2, wherein the lower bases of the projections are 30 to 200 μm in diameter.

10. (Previously Presented) The interface for a transdermal drug administration device according to claim 3, wherein the lower bases of the projections are 30 to 200 μm in diameter.

11. (Previously Presented) The interface for a transdermal drug administration device according to claim 2, wherein the openings are 50 to 2000 μm in diameter.

12. (Previously Presented) The interface for a transdermal drug administration device according to claim 3, wherein the openings are 50 to 2000 μm in diameter.

13. (Previously Presented) The interface for a transdermal drug administration device according to claim 4, wherein the openings are 50 to 2000 μm in diameter.

14. (Previously Presented) The interface for a transdermal drug administration device according to claim 2, wherein the ratio between the number of the openings and the number of the projections is 1:1 to 1:2.

15. (Previously Presented) The interface for a transdermal drug administration device according to claim 3, wherein the ratio between the number of the openings and the number of the projections is 1:1 to 1:2.

16. (Previously Presented) The interface for a transdermal drug administration device according to claim 4, wherein the ratio between the number of the openings and the number of the projections is 1:1 to 1:2.

17. (Previously Presented) The interface for a transdermal drug administration device according to claim 5, wherein the ratio between the number of the openings and the number of the projections is 1:1 to 1:2.

18-20. (Cancelled)